About Us - Sunshine Lake Pharma Co., Ltd.

Company Introduction Development History Honors Contact Us

About Us

Company Introduction Development History Honors Contact Us

Company Profile

Sunshine Lake Pharma Co., Ltd. was founded in 2003. It is a vertically integrated pharmaceutical company engaging in research and development, production and commercialization of pharmaceutical products with a focus on innovative drugs and are also involved in modified new drugs, generic drugs and biosimilars. With over two-decade of experience, the Company has built independent research and development platforms, production facilities that meet the international standards and a comprehensive sales network. The Company strategically focuses on therapeutic areas of infectious diseases, chronic diseases and oncology.

Driven by its in-house research and development, the company has developed a diverse and robust product portfolio. As of June 2025, the company had 150 approved drugs in various countries and regions, including China, the United States and Europe. The company also had more than 100 drugs in the pipeline, including 49 Class I innovative drug candidates in China, among which one innovative drug candidate was under the NMPA’s review for launching and ten innovative drug candidates were in Phases II or III clinical trials. The company is also one of the few Chinese pharmaceutical companies to have successfully developed and brought 3 Class 1 innovative drugs to market, with 1 Class 1 innovative drug submitted for marketing approval. Furthermore, the company is committed to applying AI technology across various stages of drug R&D and has established multiple advanced AI-driven models to enhance its innovation capabilities.

Through its integrated capabilities in research and development, production, and commercialization, the company has successfully created a virtuous business cycle. Its strong research and development and production capabilities have facilitated the successful commercialization of its products. The ample operating cash flow generated from product sales enables the company to continue investing in research and development, production, and marketing. Through this virtuous cycle, the company can continuously strengthen innovative R&D, further enhance its product portfolio and expand its market share, thereby ultimately achieving sustainable business growth and maintaining long-term competitive advantages.

21

Established in 2003

6000 +

Current Staff

100 +

Projects in Progress

2400 +

Patents Awarded

1100 +

Research Personnel

Corporate Culture

01.

Corporate Mission

Scientific innovation of new drugs for high-quality of healthy life.
02.

Corporate Vision

Committed to becoming a vertically integrated world-class pharmaceutical company under the dual driving forces of innovation and internationalization, supported by our excellent commercialization capabilities
03.

Character of HEC People

Loyalty Discipline Planning Innovation
04.

Goals of Organizational Building

A Combat-Ready Army, A Cultivating Talent School, A Harmonious and Caring Family

Development Strategy

In order to achieve sustainable growth, the company focus on upgrading key research，development platforms， further strengthening a diversified and robust drug pipeline.

With internationalization being key development strategy, the company aims to accelerate our expansion into global market and strive to become an international pharmaceutical company

Strengthening brand awareness and accelerating commercialization of approved drugs.

Attracting and developing global pharmaceutical talents by establishing a modern HR system that promotes and incentivizes career development.

Actively seeking and collaborating with global strategic partners.

Production Bases

Guangdong Dongguan Songshan Lake Formulation Plant

Guangdong Dongguan Songshan Lake Formulation Plant

A solid dosage formulation facility serving domestic and international markets.

Guangdong Songshan Lake Biologics Formulation Plant

Guangdong Songshan Lake Biologics Formulation Plant

Yidu Base Plot 1 – Formulation Plant

Yidu Base Plot 1 – Formulation Plant

The Most Comprehensive Domestic Insulin portfolio

Marketed products include recombinant human insulin, insulin glargine, insulin aspart, and insulin aspart 30.

HEC API Yichang Co., Ltd.

HEC API Yichang Co., Ltd.

Chemical API manufacturing plant featuring advanced enzymatic catalysis, metal catalysis, and continuous flow chemistry platforms, with comprehensive quality systems, EHS systems, and core CDMO (CMO) operations.

Yidu Base Plot 3

Yidu Base Plot 3

宜都基地二号地

Development History

2024

The Company submitted a listing application to the NMPA in respect of major product, Olorigliflozin Capsules, a Category 1 new drug, and the application was accepted.
The Company obtained clinical trial approval for HEC169584, which is first new small molecule drug candidate discovered through AIDD.
Executed an exclusive license and commercialization agreement with Apollo Therapeutics Group Limited in respect of our product candidate HEC88473.
Through a licensing agreement, we have granted Shenyang Sunshine Pharmaceutical Co., Ltd. exclusive commercialization rights of Clifutinib Besylate in
respect of specific indications in China.

2023

Submitted a listing application to the NMPA in respect of major products, Netanasvir Phosphate Capsules and Encofosbuvir Tablets, which are Category 1 new drugs, and the application was accepted.
The Company was restructured into a joint stock limited company.

2022

Company’s Fingolimod capsules became the first generic drug in China to successfully challenge the patent of a U.S. overseas drug.

2021

Company’s insulin analog insulin glargine injection was approved for marketing by the NMPA.

2020

Introduced Pre-Listing Investors.
The Company's first Class I innovative drug developed in-house, Dongweien (emitasvir phosphate), was approved for listing by the NMPA through the priority review and approval process.

2017

The first innovative drug, Yinfenidone, received clinical trial approval from the U.S. FDA and received FDA’s orphan drug designation in the same year.

2015

Approved by the Ministry of Science and Technology of the PRC to establish a state key laboratory for the R&D of new anti-infective drugs.

2012

The first product in Europe, Azithromycin tablets was approved, which was listed in Germany under its own brand in the same year.

2006

Our Group’s main product, oseltamivir phosphate, received patent authorization from Roche.

2005

The Company established a research institute and began to build an R&D team as well as an independent R&D platform.

2003

The Company was established in Dongguan, Guangdong Province and started to engage in pharmaceutical business.

Major Honors

State Key Laboratory of Anti-lnfective Drug Development
Postdoctoral Research Workstation
National Intellectual Property Model Enterprise

2017–Present

2025

2025The 25th China Patent Gold Award — Oseltamivir phosphate granules and its preparation method

2024

2024First Class Sci-Tech Advancement Award of Guangdong Province for 2023

2024The First Tier of the “Top 100 in Research and Development of Chinese Pharmaceutical Industry for 2024” List

2023

2023State Key Laboratory of Anti-lnfective Drug Development

2023The First Tier of the “Top 100 Chinese Pharmaceutical Innovators for 2022 and 2023” List

2023Top 100 Invention Patents in the Global Biomedical Industry in 2022 (No. 4 in China)

20232023 Pharmaceutical Industry Competitiveness Top 100 List

2023National High-Tech Enterprise

2023Pharmaceutical R&D Comprehensive Strength Ranking TOP 20 List

2023The Second Prize of the Beijing Science and Technology Progress Award

2023The “Most Innovative Enterprise with R&D Strength “in the 4th China Biopharmaceutical Industry Chain Innovation List for 2023

2023The “Principal” Enterprise of the Biopharmaceutical and High-end Medical Device Industry Chain

20232023 Influenza Medicine Brand List

20232023 Most Valuable Collaboration Item in Chinese Chain Pharmacies

2023Most Popular Star Product in Pharmacies

2022

2022Golden Horse Award for the Most Innovative Enterprise with the Best R&D Strength

2022 China Pharmaceuticals – Top Brand of Anti-infective Drugs in Hospital Terminal of China’s Pharmaceutical Brands

2021

2021Enterprise Technology Center of Guangdong Province

2021Breakthrough New Drug of the Year at the 13th Health China Forum

2021Technological Giant, the Invisible Champion of the Subdivision of Pillar Industries in Hubei Province

2021Best ESG Award of the 5th Golden Hong Kong Stocks Awards

2021“Enterprise Management Award” of the Pharmaceutical Industry in the “13th Five-Year Plan”

2020

2020Top 100 List of China’s Pharmaceutical Industry

2017

2017National Intellectual Property Demonstration Enterprise

Sunshine Lake Pharma

Address
HEC Science Park, 368, Zhen'an Road, Chang'an Town, Dongguan, Guangdong
TEL：
0769-85315888
FAX：
0769-85370206
Email:
info@hec.cn

Pharmacovigilance:

Reporting Adverse Drug Reactions/Events

Contact Department: HEC Pharmacovigilance Department

Email: Drugsafety@hec.cn

After-Sales Service:

Sales Hotline: 0769-85370280

Medical Inquiry Hotline: 400-670-7855 (China Toll-Free)

Medication Consultation: HEC Planet

HEC Planet

Any personal information provided to HEC related to adverse events or other pharmacovigilance activities will be used solely for the purposes stated in this notice. This information is vital for public health and will be utilized to detect, assess, understand, and prevent adverse reactions or other medicine-related problems. In compliance with the Personal Information Protection Law, we collect and process your information to fulfill our legal obligations regarding pharmacovigilance. We may also be required to report this information to regulatory authorities. Your information will not be used for any other purposes.